In vitro and in vivo inhibition of the T315I mutant BCR/ABL kinase.

被引：2

作者：

Zhu, Hong ^{[1
]}

Hanna, Ehab ^{[1
]}

Lohse, Dan ^{[1
]}

Stoughton, Silva ^{[1
]}

Tam, Betty ^{[1
]}

Barrett, Kathy ^{[1
]}

Noronha, Glenn ^{[1
]}

Dneprovskaia, Elena ^{[1
]}

Cao, Jon ^{[1
]}

Chow, Chun ^{[1
]}

Hwang, Linda ^{[1
]}

Mak, Chiching ^{[1
]}

McPherson, Andy ^{[1
]}

Palanki, Moorthy ^{[1
]}

Pathak, Ved P. ^{[1
]}

Renick, Joe ^{[1
]}

Soil, Richard ^{[1
]}

Zeng, Binqi ^{[1
]}

Hood, John ^{[1
]}

机构：

[1] TargeGen Inc, San Diego, CA USA

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.2182.2182

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2182

引用

页码：619A / 619A

页数：1

共 50 条

[1] Inhibition of the drug-resistant T315I mutant of BCR-Abl
Zhang, W.
EJC SUPPLEMENTS, 2006, 4 (12): : 54 - 54
[2] Activity of a novel Aurora kinase inhibitor against the T315I mutant form of BCR-ABL:: In vitro and in vivo studies
Akahane, Daigo
Tauchi, Tetsuzo
Okabe, Seiichi
Nunoda, Kousuke
Ohyashiki, Kazuma
CANCER SCIENCE, 2008, 99 (06) : 1251 - 1257
[3] Crystal structure of the T315I mutant of abl kinase
Zhou, Tianjun
Parillon, Lois
Li, Feng
Wang, Yihan
Keats, Jeff
Lamore, Sarah
Xu, Qihong
Shakespeare, William
Dalgarno, David
Zhu, Xiaotian
CHEMICAL BIOLOGY & DRUG DESIGN, 2007, 70 (03) : 171 - 181
[4] Combined Effects of a Pan-ABL1 Kinase Inhibitor, Ponatinib and Dasatinib Against T315I Mutant Forms of BCR-ABL1: In Vitro and In Vivo Studies
Tauchi, Tetsuzo
Katagiri, Seiichiro
Okabe, Seiichi
Ashihara, Eishi
Kimura, Shinya
Maekawa, Taira
Ohyashiki, Kazuma
BLOOD, 2011, 118 (21) : 1063 - 1064
[5] A Type-II Kinase Inhibitor Capable of Inhibiting the T315I "Gatekeeper" Mutant of Bcr-Abl
Choi, Hwan Geun
Ren, Pingda
Adrian, Francisco
Sun, Fangxian
Lee, Hyun Soo
Wang, Xia
Ding, Qiang
Zhang, Guobao
Xie, Yongping
Zhang, Jianming
Liu, Yi
Tuntland, Tove
Warmuth, Markus
Manley, Paul W.
Mestan, Juergen
Gray, Nathanael S.
Sim, Taebo
JOURNAL OF MEDICINAL CHEMISTRY, 2010, 53 (15) : 5439 - 5448
[6] Emerging strategies for the treatment of mutant Bcr-Abl T315I myeloid leukemia
Mughal, Tariq I.
Goldman, John M.
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 : S81 - S84
[7] Role of BCR in the resistance of BCR/ABL harboring the T315I mutation
Rafiei, A.
Metodieva, A. T.
Ottmann, O. G.
Serve, H.
Ruthardt, M.
Mian, A. A.
ONKOLOGIE, 2011, 34 : 5 - 5
[8] Activity of a novel aurora kinase inhibitor, VE-465, against T315I mutant form of BCR-ABL:: In vitro and in vivo studies.
Tauchi, Tetsuzo
Akahane, Daigo
Nunoda, Kosuke
Okabe, Seiichi
Ohyashiki, Kazuma
BLOOD, 2006, 108 (11) : 396A - 397A
[9] THE TRANSPHOSPHORYLATION OF BCR IN THE RESISTANCE OF BCR/ABL HARBORING THE T315I MUTATION
Ruthardt, M.
Mian, A.
Metodieva, A.
Rafiei, A.
Serve, H.
Ottmann, O.
Ruthardt, M.
HAEMATOLOGICA, 2012, 97 : 2 - 2
[10] MK-0457, an Aurora kinase and BCR–ABL inhibitor, is active in patients with BCR–ABL T315I leukemia
F J Giles
R T Swords
A Nagler
A Hochhaus
O G Ottmann
D A Rizzieri
M Talpaz
J Clark
P Watson
A Xiao
B Zhao
D Bergstrom
P D Le Coutre
S J Freedman
J E Cortes
Leukemia, 2013, 27 : 113 - 117

← 1 2 3 4 5 →